$650m buys the group rights to RemeGen’s RC148.
ApexOnco Front Page
Recent articles
Things look grim for Atara, which had been relying on a milestone from Pierre Fabre.
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
Big pharma interest remains, but the mood is fast turning gloomy.
The recently unveiled conjugate DS3610a is to start phase 1.
A phase 3 trial of the Scorpion-originated tersolisib will be in first-line breast cancer.
So who else could be interested in the oestrogen degrader?
After menin, the company tries again with farnesyl transferase.
